AxoGen Inc. (NASDAQ:AXGN) – Lake Street Capital issued their Q1 2018 earnings per share (EPS) estimates for shares of AxoGen in a note issued to investors on Wednesday. Lake Street Capital analyst B. Jackson expects that the firm will post earnings per share of $0.01 for the quarter. Lake Street Capital currently has a “Buy” rating and a $11.00 target price on the stock. Lake Street Capital also issued estimates for AxoGen’s Q2 2018 earnings at $0.03 EPS and Q3 2018 earnings at $0.04 EPS.

Other research analysts have also recently issued reports about the stock. Wedbush restated an “outperform” rating and set a $12.00 price target on shares of AxoGen in a report on Friday. JMP Securities reiterated a “buy” rating on shares of AxoGen in a research note on Tuesday.

Earnings History and Estimates for AxoGen (NASDAQ:AXGN)

TRADEMARK VIOLATION NOTICE: This article was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another domain, it was stolen and republished in violation of United States and international copyright & trademark law. The original version of this article can be read at https://www.thecerbatgem.com/2016/11/26/axogen-inc-expected-to-post-q1-2018-earnings-of-0-01-per-share-axgn.html.

Shares of AxoGen (NASDAQ:AXGN) traded up 0.57% on Thursday, reaching $8.80. 111,646 shares of the company were exchanged. AxoGen has a 12-month low of $4.52 and a 12-month high of $9.88. The stock’s market capitalization is $289.50 million. The firm has a 50 day moving average price of $8.68 and a 200-day moving average price of $7.66.

AxoGen (NASDAQ:AXGN) last announced its quarterly earnings data on Wednesday, November 2nd. The company reported ($0.08) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.08). AxoGen had a negative net margin of 33.02% and a negative return on equity of 292.94%.

In related news, CEO Karen L. Zaderej bought 10,000 shares of the company’s stock in a transaction on Friday, October 7th. The shares were purchased at an average cost of $7.50 per share, for a total transaction of $75,000.00. Following the completion of the purchase, the chief executive officer now directly owns 242,147 shares in the company, valued at $1,816,102.50. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP John P. Engels bought 4,000 shares of the company’s stock in a transaction on Friday, October 7th. The stock was bought at an average price of $7.50 per share, for a total transaction of $30,000.00. Following the completion of the purchase, the vice president now owns 98,425 shares of the company’s stock, valued at $738,187.50. The disclosure for this purchase can be found here. 9.33% of the stock is currently owned by company insiders.

TRADEMARK VIOLATION NOTICE: This article was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another domain, it was stolen and republished in violation of United States and international copyright & trademark law. The original version of this article can be read at https://www.thecerbatgem.com/2016/11/26/axogen-inc-expected-to-post-q1-2018-earnings-of-0-01-per-share-axgn.html.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AXGN. BlackRock Fund Advisors boosted its position in AxoGen by 1,049.1% in the second quarter. BlackRock Fund Advisors now owns 634,132 shares of the company’s stock worth $4,363,000 after buying an additional 578,948 shares during the last quarter. Vanguard Group Inc. boosted its position in AxoGen by 61.5% in the second quarter. Vanguard Group Inc. now owns 775,448 shares of the company’s stock worth $5,335,000 after buying an additional 295,294 shares during the last quarter. State Street Corp bought a new position in AxoGen during the second quarter worth $1,885,000. Summit Partners Public Asset Management LLC bought a new position in AxoGen during the third quarter worth $2,376,000. Finally, Waddell & Reed Financial Inc. bought a new position in AxoGen during the second quarter worth $1,371,000. Hedge funds and other institutional investors own 54.43% of the company’s stock.

5 Day Chart for NASDAQ:AXGN

Receive News & Stock Ratings for AxoGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen Inc. and related stocks with our FREE daily email newsletter.